Rivaroxaban
No
No
Patient Alert Card
Medical Assistance Fund
Active ingredient: Rivaroxaban
General information
Subsidy Information and Financing Scheme
[MAF] Rivaroxaban Tablet 15 mg, 20 mg
Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA2DS2-VASc score of 1 or more for men, and 2 or more for women
*This excludes patients with rheumatic mitral stenosis or prosthetic heart valvesTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT
Drug Guidance for Subsidy
Not Applicable
Post Marketing Information
PAC 24/02/2026 Patient Alert Card: Xarelto® (rivaroxaban) 1 mg/mL granules for oral suspension
PAC 19/11/2025 Rivaroxaban Tablets Alert Card KLD
PAC 24/07/2025 Patient Alert Card: Xarelto® rivaroxaban
PAC 30/05/2025 PATIENT ALERT CARD: Estaelto 10 mg, Estaelto 15 mg, Estaelto 20 mg
PAC 17/01/2025 Patient Alert Card Rivaroxaban: RIVASON-15, RIVASON-20
PAC 22/03/2024 PATIENT ALERT CARD: INVAROX 2.5 mg, INVAROX 10 mg, INVAROX 15 mg, INVAROX 20 mg
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 15 mg |
|
Tablet 20 mg |
|
Tablet, Film Coated 2.5 mg |
|
Tablet, Film Coated 10 mg |
|
Granule, For Suspension 1 mg/mL |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.
